Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.
about
Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.A risk-adapted approach to acute GVHD treatment: are we there yet?Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.
P2860
Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Response endpoints and failure ...... ute graft-versus-host disease.
@en
Response endpoints and failure ...... ute graft-versus-host disease.
@nl
type
label
Response endpoints and failure ...... ute graft-versus-host disease.
@en
Response endpoints and failure ...... ute graft-versus-host disease.
@nl
prefLabel
Response endpoints and failure ...... ute graft-versus-host disease.
@en
Response endpoints and failure ...... ute graft-versus-host disease.
@nl
P2093
P2860
P50
P1433
P1476
Response endpoints and failure ...... ute graft-versus-host disease.
@en
P2093
Paul A Carpenter
Paul J Martin
Yoshihiro Inamoto
P2860
P304
P356
10.3324/HAEMATOL.2013.093062
P577
2013-09-20T00:00:00Z